CAS-ViewAlert

View Alert


		Versions:

Originator:	National Patient Safety Alert - DHSC
Issue date:	Originally issued on 08-Apr-2026 13:39:03. This version was issued on 08-Apr-2026 13:39:03
This alert has been issued to:
	Care Trusts Mental Health Trusts Specialists Trusts Learning Disabilities Trusts Mental Health & Social Care Trusts Ambulance Trusts Mental Health & Learning Disabilities Trusts Acute Trusts Community Trusts
	Other contacts Independent Healthcare Providers (registered with CAS) Clinical Commissioning Groups NHS Regional Offices Social Care Providers (registered with CAS) Special Health Authorities Territorial CMOs in Northern Ireland, Scotland & Wales NHS 111 and Out of hours providers Integrated Care Boards DHSC Supply Disruption - Medicines Primary Care Networks
Action category:	Action
Title:	Shortage of dinoprostone 3mg vaginal tablets and 1mg/2.5ml, 2mg/2.5ml vaginal gel
Broadcast content:	Pfizer has advised that quality issues affecting the raw materials used in manufacturing have resulted in supply interruptions for their Prostin^® E2 (dinoprostone) range, as follows: Prostin^® E2 3 mg vaginal tablets (pessary): unavailable until October 2026 Prostin^® E2 1 mg/2.5 ml gel: unavailable from 4 May to 3 August 2026 Prostin^® E2 2 mg/2.5 ml gel: unavailable from 13 April to 7 September 2026. Other uterotonic products remain available and can support additional demand in varying amounts: Propess® (dinoprostone) 10 mg vaginal delivery system can support full demand Angusta® (misoprostol) 25 micrograms tablets can support partial demand Oxytocin 5 units/1 ml and 10 units/1 ml ampoules can support partial demand Limited quantities of unlicensed dinoprostone vaginal tablets and gels can be sourced, but lead times may vary.
Alert reference:	NatPSA/2026/003/DHSC
Action underway deadline:	08-Apr-2026
Action complete deadline:	20-Apr-2026
Attachments:	NatPSA_2026_003_DHSC.pdf